NeuraMetrix
NeuraMetrix is a private medical device company that has developed a passive digital biomarker platform measuring typing cadence on a personal computer to detect and monitor neurological diseases and psychiatric disorders, serving physicians, patients, pharmaceutical trial sponsors, and academic researchers; it holds FDA Breakthrough Device designation for Parkinson's Disease.
- Company typePrivate
- Founded2017
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What NeuraMetrix does
NeuraMetrix, Inc. is a private medical device company headquartered in Asheville, North Carolina, operating with a distributed team of approximately ten members across the United States, Europe, and Asia. Originally incorporated in 2012 as a behavioral-biometrics company focused on password elimination via typing cadence, the company pivoted in 2017-2018 to neurotechnology after Dr. Robert W. Mahley of the Gladstone Institutes recognized the potential of keystroke timing patterns for neurological disease detection. Its flagship platform, NeuraMetrix TC, is a passive digital biomarker that measures typing cadence — dwell times and flight times — running in the background on a patient's own Windows PC without active participation. Raw keystroke data is processed locally to remove identifying information, batched in 1,000-keystroke windows (often totaling ~10,000 keystrokes per day), and uploaded to NeuraMetrix's secure cloud servers where the proprietary SINCOR algorithm calculates inconsistency scores that serve as a quantitative brain-health metric.
The product is delivered as three integrated components: the NeuraMetrix TC Application (passive desktop client), the NeuraMetrix Server (cloud analytics), and the NeuraMetrix Online Dashboard (clinician/researcher portal). The company holds FDA Breakthrough Device Designation for Parkinson's Disease (January 2019), though it is not yet FDA cleared or CE-marked, and has been granted patents in the US, Australia, and Japan covering the methodology and system architecture.
The company monetizes through three primary channels: (1) software licensing to neurologists, psychiatrists, and clinical sites who prescribe the patient download, (2) contract-based pharma/biotech clinical-trial services for neurologic and psychiatric drug development, and (3) regional revenue-sharing or licensing via channel partners — bioaccess for Latin America and N-Strategy Consulting Services for Asia-Pacific. Pricing is enterprise-negotiated and not publicly disclosed. Research validation is conducted with a global network of academic institutions including Boston University, Karolinska Institutet, Huntington Center Ulm, UCSF, Mayo Clinic, Lund University, Uppsala University, University of Toronto, Dutch University Medical Centers, and others.
NeuraMetrix firmographics
Firmographics- Name
- NeuraMetrix
- Legal name
- NeuraMetrix, Inc.
- Website
- https://neurametrix.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NeuraMetrix is a private medical device company that has developed a passive digital biomarker platform measuring typing cadence on a personal computer to detect and monitor neurological diseases and psychiatric disorders, serving physicians, patients, pharmaceutical trial sponsors, and academic researchers; it holds FDA Breakthrough Device designation for Parkinson's Disease.
- Ownership category
- akta.pro rank
NeuraMetrix industry classification
Industry- Product category
- Digital Health / Digital Biomarker Software
- NAICS
- Other Computer Related Services (541519)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)
Keywords
Where NeuraMetrix is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
NeuraMetrix business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
Revenue model
- Clinical Software Licensing (Physician/Clinic): NeuraMetrix TC software is prescribed/distributed by physicians and clinical trial teams to patients. The physician provides the software download link via email. The company generates revenue through software licensing to healthcare providers and clinical trial operators. Pricing is not publicly disclosed; billing is likely per-seat or subscription-based per patient or per physician/clinic.
- Pharma Drug Trial Services: NeuraMetrix provides its digital biomarker for use in pharmaceutical clinical trials for neurological and psychiatric drug development. Pharma companies use the platform to monitor trial participants' cognitive and motor performance, enabling faster go/no-go decisions, reduced heterogeneity, and fewer dropouts. Revenue likely derived from study setup fees, per-subject licensing, and data analysis services.
- Regional Distribution Partnerships: NeuraMetrix partners with regional distributors (bioaccess™ for Latin America, NSCS for Asia-Pacific) who commercialize the technology in their respective markets, likely through revenue-sharing or licensing arrangements.
Go-to-market motion3 records
Distribution channels5 records
Marketing channels7 records
NeuraMetrix product offering
Product offeringCore offering
NeuraMetrix provides the NeuraMetrix TC platform, a passive digital biomarker that detects and monitors neurological diseases and psychiatric disorders by analyzing typing cadence (keystroke dwell and flight times) on a patient's own Windows PC or laptop. The platform comprises three components: the NeuraMetrix TC Application (passive client), the NeuraMetrix Server (cloud analytics computing the proprietary SINCOR inconsistency metric), and the NeuraMetrix Online Dashboard (visualization portal for clinicians and patients). It is sold primarily through physicians/clinics and clinical trial operators for remote, continuous brain health monitoring.
Product overview
NeuraMetrix offers a unified digital biomarker platform consisting of three integrated components: the NeuraMetrix TC Application (a passive desktop client for keystroke data collection), the NeuraMetrix Server (cloud-based analysis infrastructure running proprietary SINCOR algorithms), and the NeuraMetrix Online Dashboard (a web portal for clinicians, researchers, and patients to visualize inconsistency scores and disease progression trends). The platform measures typing cadence inconsistency as a digital biomarker for detecting and monitoring neurodegenerative diseases (Parkinson's, Huntington's, Alzheimer's) and psychiatric disorders (depression, bipolar disorder).
Differentiator
Problem solved
Functional benefit
Products and services
- NeuraMetrix TC Application Passive desktop client software that runs in the background on a user's Windows PC or laptop, collecting keystroke timing data (dwell and flight times) whenever the keyboard is used. The software is downloaded via email link sent by a physician or clinical trial team, requires no active participation, and never stores typed content — only timing metadata.
- NeuraMetrix Server Secure cloud-based server infrastructure that receives typing cadence data batches from the TC Application, performs outlier analysis, and computes the proprietary SINCOR (inconsistency) metric using patented algorithms.
- NeuraMetrix Online Dashboard Web portal (portal.neurametrix.com) that visualizes the patient's SINCOR inconsistency score as a longitudinal line graph for healthcare providers, research institutions, and (when permitted) patients, enabling monitoring of brain health trends over time.
Quantifiable outcome
- 65 million data points collected and analyzed in a single study (154 subjects, 90 days)
- +4 more outcomes
Companies that use NeuraMetrix
Customer profileNamed customers14 records
Segments4 records
Ideal customer profiles3 records
NeuraMetrix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature6 records
NeuraMetrix partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered flagship, core and minor.
- Boston University School of MedicineflagshipBoston University School of Medicine selected NeuraMetrix's digital biomarker to participate in the Precision Brain Health Initiative, funded by the American Heart Association in collaboration with global philanthropist Bill Gates. NeuraMetrix is one of the selected technologies in this major brain health program. Active research programs include heart problems and dementia, with planned Alzheimer's studies.
- Huntington Center Ulm, Ulm University, GermanyflagshipNeuraMetrix and Huntington Center Ulm (Department of Neurology, Ulm University, Germany) jointly published a peer-reviewed research article: 'Monitoring the Phenotype in Huntington Disease by Analysis of Keyboard Typing During Real Life Computer Use' in the Journal of Huntington's Disease. The study demonstrated that the digital biomarker can separate Huntington's mutation carriers with no visible symptoms into two groups: disease-not-yet-active and disease-has-already-begun.
- bioaccess™coreOrlando-based contract research organization (CRO) and market access consulting firm dedicated to helping innovative Medtech companies succeed with market expansion in Latin America. bioaccess™ and NeuraMetrix entered a partnership agreement to conduct clinical research and commercialize the digital brain health monitoring biomarker based on typing cadence in Latin America. This is a key channel partnership for NeuraMetrix to reach patients and healthcare providers in Latin American markets including Colombia.
- N-Strategy Consulting Services (NSCS)coreNSCS, founded by Nathanael Noiraud, with its founder and CEO, accelerates and invests in NeuraMetrix's Asia-Pacific market entry. NSCS provides market entry strategy, business development, and investment to establish NeuraMetrix in Malaysia and other Asia-Pacific markets.
- McKinsey & Company (J.P. Morgan Healthcare Conference)minorNeuraMetrix showcased its technology at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California, where the FDA Breakthrough Device designation was announced. The company has also been selected to present at McKinsey's Early-Stage Investor Conference (ESIC) in June 2022.
- SharpBrains (Brainnovations Competition)minorNeuraMetrix won the SharpBrains Brainnovations competition (January 2018) for its innovative digital biomarker technology. The competition win provided visibility and recognition in the digital brain health ecosystem.
- Michael J. Fox Foundation (Fox Trial Finder)flagshipNeuraMetrix completed a landmark study with the Michael J. Fox Foundation's Fox Trial Finder program. 154 subjects were monitored for 90 days, collecting and analyzing 65 million data points. The study demonstrated the ability to distinguish diagnosed Parkinson's patients from healthy subjects and monitor disease progression, identifying patients whose variability was under control, out of control, and worsening.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
NeuraMetrix competitors and assessment
Company assessmentDirect peers
- Altoida: Digital biomarker platform that uses cognitive and motor tasks on smartphones/tablets to predict and diagnose Alzheimer's and MCI. Directly comparable to NeuraMetrix as a digital neurological biomarker seeking FDA pathway and pharma trial adoption.
- Cambridge Cognition: Provider of computerized cognitive assessments (e.g., CANTAB) widely used in pharma clinical trials and clinical research for neurological and psychiatric conditions. Comparable in serving pharma CNS trial sponsors with objective cognitive endpoints.
- Cumulus Neuroscience: Digital biomarker company building a multi-modal at-home neurology platform for CNS clinical trials and clinical practice across conditions like depression and Alzheimer's. Closely comparable in modality (passive/remote measurement) and pharma trial positioning.
- BrainCheck: Digital cognitive assessment platform used by physicians and clinical researchers to detect and monitor cognitive impairment. Overlaps with NeuraMetrix in clinical decision support for neurology and in clinician-driven workflows.
Emerging players
- Linus Health: Digital cognitive health company focused on early detection of dementia and other neurological conditions via tablet-based assessments. Adjacent emerging competitor targeting similar early-detection use cases in neurology practices.
Broad incumbents
- Evidation Health: Large-scale digital health measurement platform that captures continuous behavioral and physiological data from consented consumers for research and pharma. Comparable in mining passive digital signals for health insights, though broader in scope.
- Akili Interactive: Public digital therapeutics company with FDA-cleared products for ADHD and other cognitive conditions. Comparable in pursuing prescription digital products for CNS indications, but delivers active treatment rather than passive monitoring.
- Clario (formerly Bioclinica): Major clinical trial technology and imaging/biomarker vendor serving pharma CNS trials at scale. Comparable as a vendor competing for pharma digital-endpoint budgets, though with a much broader portfolio including imaging and eCOA.
- Roche / Genentech (Floodlight): Major pharma with Floodlight, a smartphone-based passive digital biomarker program for MS and other neurological diseases. Represents the kind of vertically integrated, well-capitalized competitor that can bundle digital biomarkers into its own drug commercialization.
- Medidata (Dassault Systèmes): Dominant clinical trial technology platform with expanding digital biomarker and sensor capabilities acquired through its ecosystem. Comparable as a platform-of-record for CNS pharma trials where NeuraMetrix seeks to be embedded.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
NeuraMetrix social profiles
Digital presenceNeuraMetrix financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuraMetrix leadership team
Management profileNumber of profiles
Profiles5 records
NeuraMetrix funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuraMetrix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuraMetrix
What does NeuraMetrix do?
NeuraMetrix provides the NeuraMetrix TC platform, a passive digital biomarker that detects and monitors neurological diseases and psychiatric disorders by analyzing typing cadence (keystroke dwell and flight times) on a patient's own Windows PC or laptop. The platform comprises three components: the NeuraMetrix TC Application (passive client), the NeuraMetrix Server (cloud analytics computing the proprietary SINCOR inconsistency metric), and the NeuraMetrix Online Dashboard (visualization portal for clinicians and patients). It is sold primarily through physicians/clinics and clinical trial operators for remote, continuous brain health monitoring.
Is NeuraMetrix a public or private company?
NeuraMetrix is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was NeuraMetrix founded?
NeuraMetrix was founded in 2017. It employs 1 to 10 people.
Where is NeuraMetrix based?
NeuraMetrix is headquartered in San Francisco, United States, in the North America region.
How does NeuraMetrix make money?
Three revenue lines are on record. Clinical Software Licensing (Physician/Clinic) is the primary driver. The others are pharma Drug Trial Services and regional Distribution Partnerships.
Who are NeuraMetrix's main competitors?
Direct peers on record are Altoida, Cambridge Cognition, Cumulus Neuroscience and BrainCheck. Linus Health is listed as an emerging player. Broad incumbents are Evidation Health, Akili Interactive, Clario (formerly Bioclinica), Roche / Genentech (Floodlight) and Medidata (Dassault Systèmes).
Does NeuraMetrix have an API?
No public API is recorded for NeuraMetrix.
What industry is NeuraMetrix in?
NeuraMetrix's product category is Digital Health / Digital Biomarker Software. Its primary akta.pro industry code is HLALAFAJ, Neurology RPM (epilepsy, Parkinson’s, MS monitoring). Its NAICS code is 541519 and its SIC code is 3841.